Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Brainsway ( (BWAY) ) is now available.
BrainsWay reported a significant 29% increase in revenue for the third quarter of 2025, reaching $13.5 million, and a notable rise in net profit by 137% to $1.6 million compared to the previous year. The company also announced FDA clearance for an accelerated Deep TMS protocol for major depressive disorder, and made strategic investments to enhance its market presence, including a $5 million investment in Neurolief Ltd. These developments indicate strong market positioning and potential for sustainable growth through strategic collaborations and expanded treatment indications.
The most recent analyst rating on (BWAY) stock is a Buy with a $18.50 price target. To see the full list of analyst forecasts on Brainsway stock, see the BWAY Stock Forecast page.
Spark’s Take on BWAY Stock
According to Spark, TipRanks’ AI Analyst, BWAY is a Outperform.
Brainsway’s strong financial performance and positive earnings call are the most significant factors driving the score. The company’s robust balance sheet and improved cash flow generation enhance its financial stability. However, the high P/E ratio and absence of a dividend yield are concerns for valuation. Technical indicators suggest a positive trend, but potential oversold conditions warrant caution.
To see Spark’s full report on BWAY stock, click here.
More about Brainsway
BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The company specializes in Deep Transcranial Magnetic Stimulation (Deep TMS) technology, which has received FDA clearance for treating major depressive disorder, obsessive-compulsive disorder, and smoking addiction. Founded in 2003, BrainsWay operates in the United States and Israel, focusing on expanding awareness and access to its innovative treatments.
Average Trading Volume: 75,678
Technical Sentiment Signal: Buy
Current Market Cap: $318.8M
For an in-depth examination of BWAY stock, go to TipRanks’ Overview page.